372 related articles for article (PubMed ID: 34065940)
21. Prophylaxis and therapy of plague.
Oyston PC; Williamson ED
Expert Rev Anti Infect Ther; 2013 Aug; 11(8):817-29. PubMed ID: 23977937
[TBL] [Abstract][Full Text] [Related]
22. Yersinia pestis with regulated delayed attenuation as a vaccine candidate to induce protective immunity against plague.
Sun W; Roland KL; Kuang X; Branger CG; Curtiss R
Infect Immun; 2010 Mar; 78(3):1304-13. PubMed ID: 20086087
[TBL] [Abstract][Full Text] [Related]
23. An encapsulated Yersinia pseudotuberculosis is a highly efficient vaccine against pneumonic plague.
Derbise A; Cerdà Marín A; Ave P; Blisnick T; Huerre M; Carniel E; Demeure CE
PLoS Negl Trop Dis; 2012; 6(2):e1528. PubMed ID: 22348169
[TBL] [Abstract][Full Text] [Related]
24. Yersinia pestis and the plague.
Rollins SE; Rollins SM; Ryan ET
Am J Clin Pathol; 2003 Jun; 119 Suppl():S78-85. PubMed ID: 12951845
[TBL] [Abstract][Full Text] [Related]
25. Live-attenuated Yersinia pestis vaccines.
Wang X; Zhang X; Zhou D; Yang R
Expert Rev Vaccines; 2013 Jun; 12(6):677-86. PubMed ID: 23750796
[TBL] [Abstract][Full Text] [Related]
26. The Yersinia pestis GTPase BipA Promotes Pathogenesis of Primary Pneumonic Plague.
Crane SD; Banerjee SK; Eichelberger KR; Kurten RC; Goldman WE; Pechous RD
Infect Immun; 2021 Jan; 89(2):. PubMed ID: 33257531
[No Abstract] [Full Text] [Related]
27. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E
Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706
[TBL] [Abstract][Full Text] [Related]
28. A non-invasive in vivo imaging system to study dissemination of bioluminescent Yersinia pestis CO92 in a mouse model of pneumonic plague.
Sha J; Rosenzweig JA; Kirtley ML; van Lier CJ; Fitts EC; Kozlova EV; Erova TE; Tiner BL; Chopra AK
Microb Pathog; 2013 Feb; 55():39-50. PubMed ID: 23063826
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of the latest fluoroquinolones against experimental Yersinia pestis.
Steward J; Lever MS; Russell P; Beedham RJ; Stagg AJ; Taylor RR; Brooks TJ
Int J Antimicrob Agents; 2004 Dec; 24(6):609-12. PubMed ID: 15555886
[TBL] [Abstract][Full Text] [Related]
30. Oral vaccination against plague using Yersinia pseudotuberculosis.
Demeure CE; Derbise A; Carniel E
Chem Biol Interact; 2017 Apr; 267():89-95. PubMed ID: 27046452
[TBL] [Abstract][Full Text] [Related]
31. Yersinia pestis: still a plague in the 21st century.
Josko D
Clin Lab Sci; 2004; 17(1):25-9. PubMed ID: 15011977
[TBL] [Abstract][Full Text] [Related]
32. Human anti-plague monoclonal antibodies protect mice from Yersinia pestis in a bubonic plague model.
Xiao X; Zhu Z; Dankmeyer JL; Wormald MM; Fast RL; Worsham PL; Cote CK; Amemiya K; Dimitrov DS
PLoS One; 2010 Oct; 5(10):e13047. PubMed ID: 20976274
[TBL] [Abstract][Full Text] [Related]
33. Rational considerations about development of live attenuated Yersinia pestis vaccines.
Sun W; Curtiss R
Curr Pharm Biotechnol; 2013; 14(10):878-86. PubMed ID: 24372254
[TBL] [Abstract][Full Text] [Related]
34. Induction of Type I Interferon through a Noncanonical Toll-Like Receptor 7 Pathway during Yersinia pestis Infection.
Dhariwala MO; Olson RM; Anderson DM
Infect Immun; 2017 Nov; 85(11):. PubMed ID: 28847850
[No Abstract] [Full Text] [Related]
35. Deletion of Braun lipoprotein and plasminogen-activating protease-encoding genes attenuates Yersinia pestis in mouse models of bubonic and pneumonic plague.
van Lier CJ; Sha J; Kirtley ML; Cao A; Tiner BL; Erova TE; Cong Y; Kozlova EV; Popov VL; Baze WB; Chopra AK
Infect Immun; 2014 Jun; 82(6):2485-503. PubMed ID: 24686064
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy of plague prophylaxis with streptomycin, tetracycline, and rifampicin in simultaneous immunization of white mice by resistant EV NRIEG strain].
Ryzhko IV; Tsuraeva RI; Moldavan IA; Shcherbaniuk AI
Antibiot Khimioter; 2004; 49(1):17-21. PubMed ID: 15164519
[TBL] [Abstract][Full Text] [Related]
37. Yersinia pestis YopJ suppresses tumor necrosis factor alpha induction and contributes to apoptosis of immune cells in the lymph node but is not required for virulence in a rat model of bubonic plague.
Lemaître N; Sebbane F; Long D; Hinnebusch BJ
Infect Immun; 2006 Sep; 74(9):5126-31. PubMed ID: 16926404
[TBL] [Abstract][Full Text] [Related]
38. Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.
Louie A; Deziel MR; Liu W; Drusano GL
Antimicrob Agents Chemother; 2007 Aug; 51(8):2661-7. PubMed ID: 17517837
[TBL] [Abstract][Full Text] [Related]
39. [A comparative study of fluoroquinolones and 3rd-generation cephalosporins in the prevention and treatment of experimental plague caused by Yersinia pestis strains typical and serologically atypical with respect to F1].
Ryzhko IV; Shcherbaniuk AI; Tsuraeva RI; Samokhodkina ED; Kasatkina IV; Tsetskhladze NS; Pasiukov VV; Roshchina NV
Antibiot Khimioter; 1997; 42(1):12-6. PubMed ID: 9221699
[TBL] [Abstract][Full Text] [Related]
40. Polymorphisms in the lcrV gene of Yersinia enterocolitica and their effect on plague protective immunity.
Miller NC; Quenee LE; Elli D; Ciletti NA; Schneewind O
Infect Immun; 2012 Apr; 80(4):1572-82. PubMed ID: 22252870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
